The Indonesian Ministry of Health is accelerating the downstream development of the national healthcare industry to reduce reliance on imports and boost economic contribution. Indonesia's Health Minister Budi Gunadi Sadikin stated that while Indonesia can already produce many finished pharmaceutical products, around 70–80% of raw materials—particularly active pharmaceutical ingredients (APIs)—are still imported, though this has improved from over 90% previously. The government is now focusing on increasing domestic API production, with 35 types already produced locally and more in development. Strengthening the upstream supply chain is considered essential so that healthcare spending generates higher added value within the domestic economy. In addition to pharmaceuticals, the government is also developing a domestic blood plasma industry to reduce dependence on imported plasma-derived products such as immunoglobulin. Indonesia’s first plasma processing factory has been completed and is awaiting regulatory approval, with operations targeted to begin in early 2027. Overall, the initiative involves cross-sector collaboration to build a fully integrated healthcare industry ecosystem. By expanding local production of both raw materials and finished products, the government aims to stimulate GDP growth, create jobs, and ensure that healthcare spending—currently exceeding 10% of the state budget—has a stronger impact on the national economy.Source: https://industri.kontan.co.id/news/kemenkes-percepat-hilirisasi-industri-kesehatan-kurangi-ketergantungan-impor (ICE GIACARTA)

Fonte notizia: KONTAN, 24 June 2026